Arkadiusz Z Dudek
Overview
Explore the profile of Arkadiusz Z Dudek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
2284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbir E, Abdulmoneim S, Dudek A, Kukla A
Transpl Int
. 2024 Oct;
37:13322.
PMID: 39479217
Immune checkpoint inhibitor (ICI) therapy has enabled a paradigm shift in Oncology, with the treatment of metastatic cancer in certain tumor types becoming akin to the treatment of chronic disease....
2.
Patel M, Begnaud A, Blackmon S, Dudek A, Fujioka N, Harewood J, et al.
J Cancer Educ
. 2024 Oct;
PMID: 39438400
Lung cancer patient education resources that address barriers to health literacy, improve understanding, and demonstrate improved patient outcomes are limited. Our study aim was to evaluate and report on learner...
3.
Shenouda M, Gudmundsson E, Li F, Straus C, Kindler H, Dudek A, et al.
J Imaging Inform Med
. 2024 Sep;
PMID: 39266911
The purpose of this study was to evaluate the impact of probability map threshold on pleural mesothelioma (PM) tumor delineations generated using a convolutional neural network (CNN). One hundred eighty-six...
4.
Stoff R, Markovic S, McWilliams R, Kottschade L, Montane H, Dimou A, et al.
Melanoma Res
. 2024 Aug;
34(6):510-518.
PMID: 39207855
Melanoma is the deadliest form of skin cancer. The median age at diagnosis is 66. While most patients are treated with immunotherapy, the use of targeted therapy is a valid...
5.
Watt K, Rolak S, Foley D, Plichta J, Pruthi S, Farr D, et al.
Transplantation
. 2024 May;
108(12):2336-2350.
PMID: 38771067
With improved medical treatments, the prognosis for many malignancies has improved, and more patients are presenting for transplant evaluation with a history of treated cancer. Solid organ transplant (SOT) recipients...
6.
Ablooglu A, Chen W, Xie Z, Desai A, Paul S, Lack J, et al.
J Clin Invest
. 2024 Mar;
134(10).
PMID: 38502192
Clarkson disease, or monoclonal gammopathy-associated idiopathic systemic capillary leak syndrome (ISCLS), is a rare, relapsing-remitting disorder featuring the abrupt extravasation of fluids and proteins into peripheral tissues, which in turn...
7.
Sener U, Webb M, Breen W, Neth B, Laack N, Routman D, et al.
J Immunother Precis Oncol
. 2024 Feb;
7(1):1-6.
PMID: 38327758
Introduction: Proton craniospinal irradiation (pCSI) is a treatment option for leptomeningeal disease (LMD), which permits whole neuroaxis treatment while minimizing toxicity. Despite this, patients inevitably experience progression. Adding systemic therapy...
8.
Shenouda M, Gudmundsson E, Li F, Straus C, Kindler H, Dudek A, et al.
ArXiv
. 2023 Dec;
PMID: 38076518
Malignant pleural mesothelioma (MPM) is the most common form of malignant mesothelioma, with exposure to asbestos being the primary cause of the disease. To assess response to treatment, tumor measurements...
9.
Dudek A, Xi M, Scilla K, Mamdani H, Creelan B, Saltos A, et al.
JTO Clin Res Rep
. 2023 Dec;
4(12):100584.
PMID: 38046376
Introduction: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent nivolumab in the second-line therapy of unresectable mesothelioma. Methods: This was a cooperative...
10.
Smith K, Peng K, Pulido J, Weisbrod A, Strand C, Allred J, et al.
Front Immunol
. 2023 Nov;
14:1279387.
PMID: 38022659
Introduction: Metastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV)...